Abbott reports success in mid-stage psoriasis trial

Abbott Laboratories announced positive data from a mid-stage study of its experimental psoriasis drug ABT-874, a follow-up drug to Humira. Aside from the control group, researchers divided up patients into five groups which received different doses. At least 90 percent of the patients in four of the five groups saw a 75 percent improvement in the severity of their skin lesions.

- check out the release on the drug